Skip to main content
. 2016 Jan 14;5(3):454–464. doi: 10.1002/cam4.608

Table 3.

Skin toxicity grade at post‐RT by patient and clinical variables

Skin toxicity (modified grade) Skin toxicity (CTCAE grade)
0 1 2 3 4 5 P a 0–1 2–3 4–5 P b 0 1 2 3 0–1 2–3 P b
Variable N N N N N N N % N % N % N N N N P a N % N %
Total patients 4 169 77 59 74 9 173 44 136 35 83 21 4 184 195 9 188 48 204 52
Age at consent (years)
<50 – 39 15 18 24 2 0.221 39 40 33 34 26 27 0.367 – 43 53 2 0.308 43 44 55 56 0.332
50–59 1 65 37 23 24 6 66 42 60 38 30 19 1 71 78 6 72 46 84 54
≥60 3 65 25 18 26 1 68 49 43 31 27 20 3 70 64 1 73 53 65 47
Menopausal status
Pre/Peri – 56 19 23 27 3 0.433 56 44 42 33 30 23 0.719 – 61 64 3 0.996 61 48 67 52 0.933
Post 4 113 58 36 47 6 117 44 94 36 53 20 4 123 131 6 127 48 137 52
Race/ethnicity
NHW – 28 17 7 6 1 NE 28 47 24 41 7 12 0.451 – 31 27 1 0.286 31 53 28 47 0.610
HW 2 107 41 40 48 3 109 45 81 34 51 21 2 116 120 3 118 49 123 51
AA 2 28 16 11 17 5 30 38 27 34 22 28 2 31 41 5 33 42 46 58
Other – 6 3 1 3 – 6 46 4 31 3 23 – 6 7 – 6 46 7 54
Non‐AA 2 141 61 48 57 4 0.080 143 46 109 35 61 19 0.230 2 153 154 4 0.019 155 50 158 50 0.218
AA 2 28 16 11 17 5 30 38 27 34 22 28 2 31 41 5 33 42 46 58
BMI (kg/m2)
<25 ‐ 56 18 15 10 2 0.008 56 55 33 33 12 12 0.001 ‐ 62 37 2 0.004 62 61 39 39 0.002
25–29.99 1 62 28 20 21 1 63 47 48 36 22 17 1 63 68 1 64 48 69 52
≥30 3 51 31 24 43 6 54 34 55 35 49 31 3 59 90 6 62 39 96 61
Smoking history
Never 2 111 45 39 56 7 0.227 113 43 84 32 63 24 0.093 2 121 130 7 0.738 123 47 137 53 0.717
Ever 2 58 32 20 18 2 60 45 52 39 20 15 2 63 65 2 65 49 67 51
No. of comorbidities
None 1 67 34 25 24 3 NE 68 44 59 38 27 18 0.821 1 72 78 3 0.642 73 47 81 53 0.993
1 – 66 27 20 31 2 66 45 47 32 33 23 – 71 73 2 71 49 75 51
2 3 25 10 12 14 2 28 42 22 33 16 24 3 29 32 2 32 48 34 52
≥3 – 11 6 2 5 2 11 42 8 31 7 27 – 12 12 2 12 46 14 54
Disease stage
0 2 45 11 10 10 1 0.099 47 59 21 27 11 14 0.013 2 47 29 1 0.022 49 62 30 38 0.005
IA–B 1 83 35 29 40 5 84 44 64 33 45 23 1 92 95 5 93 48 100 52
IIA–IIIC 1 41 31 20 24 3 42 35 51 43 27 23 1 45 71 3 46 38 74 62
Histology
DCIS (ductal carcinoma in situ) 2 49 10 11 11 2 NE 51 60 21 25 13 15 0.004 2 51 30 2 NE 53 62 32 38 0.002
IDC (invasive ductal carcinoma) 2 108 64 47 61 7 110 38 111 38 68 24 2 121 159 7 123 43 166 57
ILC (invasive lobular carcinoma) – 11 3 1 2 – 11 65 4 24 2 12 – 11 6 – 11 65 6 35
Other – 1 – – – – 1 100 – – – – – 1 – – 1 100 – –
ER
Positive 3 133 54 46 55 8 0.493 136 45 100 33 63 21 0.518 3 145 143 8 0.275 148 49 151 51 0.233
Negative 1 35 23 13 19 1 36 39 36 39 20 22 1 38 52 1 39 42 53 58
PR
Positive 3 123 46 38 46 7 0.150 126 48 84 32 53 20 0.063 3 133 120 7 0.044 136 52 127 48 0.022
Negative 1 44 31 21 28 2 45 35 52 41 30 24 1 49 75 2 50 39 77 61
HER2
Positive – 17 7 6 8 – 0.836 17 45 13 34 8 21 0.855 – 19 19 – 0.503 19 50 19 50 0.500
Negative 2 112 62 43 58 8 114 40 105 37 66 23 2 124 151 8 126 44 159 56
Triple negative
No 3 140 60 48 58 8 0.336 143 45 108 34 66 21 0.192 3 153 153 8 0.145 156 49 161 51 0.062
Yes – 18 15 8 14 1 18 32 23 41 15 27 – 20 35 1 20 36 36 64
Chemotherapy
No 3 86 37 27 34 4 0.909 89 47 64 34 38 20 0.622 3 91 93 4 0.604 94 49 97 51 0.628
Yes 1 83 40 32 40 5 84 42 72 36 45 22 1 93 102 5 94 47 107 53
Hormone therapy
No – 56 27 20 27 3 0.966 56 42 47 35 30 23 0.784 – 60 70 3 0.668 60 45 73 55 0.379
Yes 4 113 49 39 46 6 117 46 88 34 52 20 4 124 123 6 128 50 129 50
Fractionation
Hypofractionated 2 46 10 4 5 – ≤.001 48 72 14 21 5 7 ≤.001 2 47 18 – ≤.001 49 73 18 27 ≤.001
Conventionally fractionated 2 122 67 54 69 9 124 38 121 37 78 24 2 135 177 9 137 42 186 58
Lumpectomy cavity boost
No 1 30 5 5 5 2 0.024 31 65 10 21 7 15 0.009 1 31 14 2 0.008 32 67 16 33 0.005
Yes 3 138 72 53 69 7 141 41 125 37 76 22 3 151 181 7 154 45 188 55
Breast volume
<881.3 CC (median) 4 94 34 30 27 1 0.005 99 51 66 34 28 15 0.003 4 100 85 1 0.003 105 54 88 46 0.011
≥881.3 CC – 73 42 28 43 8 73 38 67 35 53 27 – 80 106 8 80 41 113 59
Percentage of breast volume with >105% prescription dose
<51.3 (75th percentile) 3 118 48 42 45 5 0.607 121 46 90 34 50 19 0.438 3 126 127 5 0.581 129 49 132 51 0.644
≥51.3 1 43 15 9 19 1 44 50 24 27 20 23 1 45 41 1 46 52 42 48
Percentage of breast volume with >110% prescription dose
0 2 89 29 29 33 2 0.634 91 49 58 32 35 19 0.710 2 94 86 2 0.350 96 52 88 48 0.456
>0 2 72 33 22 31 4 74 45 55 34 35 21 2 77 81 4 79 48 85 52

NE, not estimable.

a

P‐value from chi‐squared test or Fisher's exact test with grade 0–1 grouped.

b

P‐value from chi‐squared test or Fisher's exact test.

Bold values indicate statistically significant findings at p < 0.05.